TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules

Por Liu, Qian, Sun, Jessica D., Wang, Jingli, Ahluwalia, Dharmendra, Baker, Amanda F., Cranmer, Lee D., Ferraro, Damien, Wang, Yan, Duan, Jian-Xin, Ammons, W. Steve, Curd, John G., Matteucci, Mark D., Hart, Charles P.
Publicado em 2012